Delivery Order SPE2DB22D3501-SPE2DB24FWF34

Award Date 7/9/24
Potential Completion Date 7/10/24
Potential Value $5.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of GARDASIL 9 SYRINGE 0.5ML pharmaceutical products to the Defense Logistics Agency (DLA), a defense agency of the U.S. government. The prime contractor is Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to federal agencies, particularly the Department of Defense and Veterans Affairs healthcare systems. The contract has a ceiling value of $11,684.60 and is a Delivery Order under a larger Indefinite...
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 ml) to the Defense Logistics Agency (DLA), a defense agency of the U.S. government. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, on July 15, 2024 with a ceiling value of $12,983.48 and a completion date of July 16, 2024. This is a firm fixed price delivery order contract, and there is no set-aside designation noted. Amerisourcebergen holds a large Indefinite...
This federal contract award is for the delivery of GARDASIL 9 SYRINGE 0.5ML to the Defense Logistics Agency (DLA), a Defense agency. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for a total ceiling value of $13,363.82. The contract is a Delivery Order with a Firm Fixed Price pricing type, with an ultimate completion date of April 19, 2023. The contract is not designated with a set-aside. AmerisourceBergen Drug Corp...
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 ml) to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor that plays a critical role in supplying medical products to federal government agencies. The contract, valued at $15,773.30, is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 and...
This federal contract award is for the delivery of GARDASIL 9 SYRINGE 0.5ML to the Defense Logistics Agency (DLA). The $23,926.46 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a completion date of September 12, 2024 and was awarded on September 11, 2024. This award is a child contract under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen...
This federal contract award is for the delivery of GARDASIL 9 SYRINGE 0.5ML to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to the prime contractor Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, on July 10, 2024 with a ceiling value of $3,652.40. The contract has a completion date of July 11, 2024 and is a firm fixed-price delivery order. This award is not associated with a...
This federal contract award is for the delivery of GARDASIL 9 syringes in 0.5 ml doses to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for a ceiling value of $2,475.32. The contract is a delivery order with a firm fixed price and has an ultimate completion date of January 28, 2025. The contract is not designated with a set-aside. Amerisourcebergen Drug Corp...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of GARDASIL 9 syringes (0.5 mL). The firm-fixed-price delivery order, valued at $14,653.72, has a completion date of November 20, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for...
This federal contract award is for the delivery of GARDASIL 9 SYRINGE 0.5ML pharmaceutical products to the Defense Logistics Agency (DLA). The contract, valued at $15,049.24, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. As a Delivery Order contract, this represents an individual order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued up to $999,999,999 through December 2025. The contract is...
This federal contract award is for the delivery of GARDASIL 9 SYRINGE 0.5ML medical products to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a firm fixed price of $5,111.46 and an ultimate completion date of December 16, 2024. It is a delivery order contract and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB24FWF34
    Delivery Order

This federal contract award is for the delivery of the pharmaceutical product GARDASIL 9 SYRINGE 0.5ML to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, on a Firm Fixed Price basis for a ceiling value of $5,146.57. The contract type is a Delivery Order with a completion date of July 10, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The contract does not have a set-aside designation.

Generated 10/8/24, 9:09 AM